Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03

[11] Tagliabue L(2008)Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers Hum Pathol 6 7104-7122

[12] Balduzzi S(2015)Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer Oncotarget 111 1065-1071

[13] von Minckwitz G(2014)EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial Br J Cancer 28 1700-1712

[14] Procter M(2017)De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the primary therapy of early breast cancer 2017 Ann Oncol 384 164-172

[15] de Azambuja E(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 13 25-32

[16] Carey LA(2012)Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol 145 143-153

[17] Perou CM(2014)Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: A multicenter retrospective observational study (JBCRG-C03 study) Breast Cancer Res Treat 10 5367-5374

[18] Livasy CA(2004)Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 161 1991-1996

[19] Reis-Filho JS(2002)Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome Am J Pathol 16 6100-6110

[20] Pusztai L(2010)Intrinsic breast tumor subtypes, race, and long-term survival in the carolina breast cancer study Clin Cancer Res 134 130-133

[11] Tagliabue L(2008)Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers Hum Pathol 6 7104-7122

[12] Balduzzi S(2015)Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer Oncotarget 111 1065-1071

[13] von Minckwitz G(2014)EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial Br J Cancer 28 1700-1712

[14] Procter M(2017)De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the primary therapy of early breast cancer 2017 Ann Oncol 384 164-172

[15] de Azambuja E(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 13 25-32

[16] Carey LA(2012)Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol 145 143-153

[17] Perou CM(2014)Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: A multicenter retrospective observational study (JBCRG-C03 study) Breast Cancer Res Treat 10 5367-5374

[18] Livasy CA(2004)Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 161 1991-1996

[19] Reis-Filho JS(2002)Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome Am J Pathol 16 6100-6110

[20] Pusztai L(2010)Intrinsic breast tumor subtypes, race, and long-term survival in the carolina breast cancer study Clin Cancer Res 134 130-133